We just completed a multi-center, randomized, placebo-controlled, double-masked, parallel-group study (NCT03226444) of 'Lacripep™' in Primary Sjogren's Syndrome Dry Eye. Lacripep is a natural constituent of tears that is deficient in dry eye.
Location: United States, Virginia, Charlottesville
Investors 3
Mentions in press and media 4
| Date | Title | Description | Source |
| 19.03.2021 | 120Water on growth tear, closes on $4.5M funding round | - | ibj.com/ar... |
| 21.03.2019 | Charlottesville Biotech Startup TearSolutions is $6.4M Close... | Charlottesville startup TearSolutions is moving ever closer to commercialization after hauling in a ... | bizjournal... |
| 07.02.2018 | Biotech with treatment for chronic dry eye disease tied to d... | The $500,000 seed round comes from two funding sources supported by Pennsylvania: Life Sciences Gree... | medcitynew... |
| - | Biotech with treatment for chronic dry eye disease tied to d... | Biotech startup Ocunova, a spin-out from the Penn State University College of Medicine, has closed a... | medcitynew... |